Indeed, a recent genome-wide siRNA screen revealed that downregulation of MASTL can cause radiosensitization in non-small cell lung cancer cell lines, further supporting MASTL as a promising and druggable target21. This evidence concerns the gene MASTL and non-small cell lung carcinoma.